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                                  INTRODUCTION
Nephropathy induced by contrast media is a significant yet underestimated problem in 
clinical practice.  With the increasing use of contrast media in diagnostic  and interventional 
procedures over the last 30 years, this form of nephropathy has become the third leading cause 
of hospital-acquired acute renal failure, accounting for 12% of all cases (1, 27).
The risk of contrast-medium nephropathy continues to be considerable, despite the use 
of newer and less nephrotoxic contrast agents in high-risk patients in recent years(2). Affected 
patients  are  at  increased  risk  of  morbidity  and  death.  They may  require  short-term 
hemodialysis,  which  can  extend  their hospital  stay  and  increase  the  risk  of  permanent 
impairment of the renal function (1, 2, 3).
The rate of contrast-medium nephropathy reported in studies that included patients with 
pre-existing renal dysfunction or diabetes mellitus in whom a standard hydration protocol was 
not administered (4,7)  is between 12% and 26%. Lower rates (3.3%) have been reported among 
patients  without  these risk factors  (5).  The reason a  number of  patients  develop acute renal 
failure  following  a  cardiac  procedure  is  the  necessity to  perform  these  procedures  in  the 
presence of pre-existing, and often non-modifiable, risk factors for renal impairment.
Many individual risk factors have been reported  (4,  5) for the development of CIN. The 
combination of two or more risk factors is rather common in daily practice, the cumulative risk 
of several variables on renal function is recognized (20). A simple risk score has been developed 
by which the risk of contrast  induced nephropathy after PCI can be simply assessed using 
readily available information (12). 
This study aims to assess the incidence of contrast induced nephropathy and identify the 
common risk  factors  of  contrast  induced  nephropathy  in  patients  undergoing  percutaneous 
coronary intervention procedures.
AIMS OF THE STUDY
The main aims of this study are 
1. To assess the incidence of contrast induced nephropathy, defined as a raise in 
post-procedural  creatinine  by  >25% over  the  baseline,  in  patients  undergoing 
cardiac catheterization studies.
2. To  identify  the  common  and  important  risk  factors  of  contrast  induced 
nephropathy in patients undergoing cardiac catheterization studies.  
REVIEW OF LITERATURE
Contrast-medium  nephropathy  is  usually  defined  as  impairment of  renal  function 
occurring within 48 hours after the administration of the contrast media(4, 5, 6). It is manifested by 
an absolute increase in the serum creatinine level of at least 44 µmol/L (5, 7, 8, 9)  or by a relative 
increase of at least 25% over the baseline value (10, 11) in the absence of another cause. In patients 
with CIN, serum creatinine rises by 24 hours in about 60% of patients and by 72 hours in more 
than 90%. Most patients described in recent series are non-oliguric and a return to baseline 
occurs over 7-10 days (28, 29).
Physicochemical characteristics of various contrast media
Nonionic  and  ionic  iodinated  contrast  media  are  currently  classified, at  the 
concentrations  required  for  diagnostic  or  interventional radiologic  and  cardiac  procedures, 
according  to  their  osmolality compared  with  the  osmolality  of  plasma.  The  high-osmolal 
contrast media (osmolality 1500–1800 mOsm/kg) are first generation agents. In fact, the so-
called low-osmolal contrast media still have an increased osmolality compared with plasma 
(600–850 mOsm/kg), while the newest nonionic radiocontrast agents have a lower osmolality, 
290 mOsm/kg, iso-osmolal to plasma.
Ionic, osmolal and molecular characteristics of contrast media
Ionic, high-osmolal monomers (1500 to 
1800 mOsm/kg)
Diatrizoate
Ionic, low-osmolal dimers (600 to 850 
mOsm/kg)
Ioxaglate
Nonionic, low-osmolal monomers (600 
to 850 mOsm/kg)
Iopamidol, Iomeprol, 
Iopromide, Iohexol, Iopentol
Nonionic, iso-osmolal dimers 
(approximately 290 mOsm/kg)
Iodixanol
Ionic monomers
These include diatrizoate, iothalamate, ioxithalamate and metrizoate, the first two being 
by far the most commonly used. All ionic monomers are salts with sodium or meglumine as the 
non-radioopaque cation and a radioopaque tri-iodinated fuly substituted benzoic acid ring as 
the  anion.  Each molecule  completely  dissociates  in  water  solution into one anion and one 
cation. As each anion contains 3 atoms of Iodine each molecule of ionic monomer provides 3 
Iodine atoms for 2 ions, giving Iodine:particle ratio of 3:2.
Non-ionic monomers
The  first  non-ionic  tri-iodinated  monomer  was  metrizamide,  but  was  replaced  by 
iohexol, iopamidol, iopromide, ioversol, ioxilan etc. Each of these molecules are tri-iodinated, 
non-ionising  compounds  therefore  in  solution  they  produce  3  atoms  of  iodine  to  every 
osmotically active particle producing an iodine :particle ratio of 3:1.
Ionic dimers
Ioxaglate (Hexabrix) is the only compound in this group. It is a mixture of sodium and 
meglumine salts of a  mono-acidic double benzene ring having 3 atoms of iodine at C2, 4 and 6 
positions.  The  total  molecule  therefore  contains  6  atoms  of  Iodine  and  in  solution  each 
molecules  dissociates  to  give  1  radioopaque  hexa-iodinated  anion  and  1  non-radioopaque 
cation (sodium or meglumine). Ioxaglate therefore has an Iodine:particle ratio of 6:2 or 3:1.
Non Ionic dimers
Iotrolan (isovist) and Iodixanol (Visipaque) are both examples of non ionizing chemicals 
each  molecule  containing  2  non-ionic  tri-iodinated  benzene  rings  linked  together.  Each 
molecule  therefore  produces  in  solution  6  atoms  of  iodine  for  one  particle  to  give  an 
Iodine:particle ratio of 6:1.
Osmolality  is  dependent on the  number of  particles  of  solute in solution and radio-
opacity is dependent on the Iodine concentration of the solution.
The  experimental  evidence  obtained thus  far  after  a  70 year search  for  a  less  toxic 
compound indicates that  the molecules and the physicochemical  characteristics  of currently 
available CM are  not  comparable.  For  example,  nonionic,  low-osmolal,  monomeric agents 
appear to be less nephrotoxic than ionic,  high-osmolal agents,  at least in patients with pre-
existing renal impairment(13,  14). Some reviewers have hypothesized that nonionic, iso-osmolal 
dimers can offer some advantages when compared with nonionic, low-osmolar monomers, but 
there is limited evidence to support this hypothesis in the medical literature(15).
ADVERSE REACTIONS          
Contrast media are known to produce reactions that can be minor (nausea, vomiting, 
urticaria,  itching and sneezing),  moderate (nephrotoxic effects,  congestive heart  failure and 
pulmonary edema), or severe (bronchospasm, anaphylaxis and even death). Most of the minor 
and moderate reactions decrease significantly by use of non-ionic contrast media.
Anaphylactoid reactions in the bodycan be: Idiosyncratic anaphylactoid reactions, Non 
idiosyncratic reactions, and a combination of the two. 
Idiosyncratic anaphylactoid reaction 
These are dreaded, serious and sometimes fatal reactions to contrast media as they occur 
rapidly and without warning.  These reactions begin either during or immediately after the 
administration  of  injection  of  the  contrast  media.  Anaphylactoid  reactions  are  not  dose 
dependent and death has been known to occur following as little as 1ml of intravenous contrast 
injection or after a full dose of contrast following a negative test dose. 
Non idiosyncratic reactions
These may be divided into chemotoxic and osmotoxic reactions, reactions due to direct 
toxicity, vasomotor and vagal reactions. These non-idiosyncratic reactions are dose dependent 
and therefore related to osmolarity and concentration and volume of contrast medium injected. 
RENAL HANDLING OF CONTRAST MEDIA
Renal haemodynamic changes 
The injection  of  CM induces  a  biphasic  haemodynamic response within the  kidney, 
causing  early,  rapid  renal  vasodilatation followed  by  prolonged  vasoconstriction,  with  an 
increase in intrarenal vascular resistances, a reduction of total renal blood flow (RBF) and a 
decrease  in  glomerular  filtration  rate (GFR).  Conversely,  the  effect  on  the  extrarenal 
vasculature is transient vasoconstriction that precedes a stable decrease in vascular peripheral 
resistances.  The  resulting  renal  ischaemia due  to  these  haemodynamic  effects  is,  in  part, 
responsible for nephropathy(16).
The  reduction  in  renal  plasmatic  flow  is  not  uniform  and  occurs especially  in  the 
medulla, since medullar perfusion and partial O2 pressure (PO2) are much lower than in the 
cortex. The ascending limb of Henle's loop in the medulla is characterized by high metabolic 
activity and increased O2 demand due to active ion transport through the membrane. Therefore, 
renal hypoxia may be a critical factor in the pathogenesis of CIN(17). Alterations in regulatory 
intrarenal  and  systemic  mechanisms, induced  by  mediators  influenced  by  CM,  seem  to 
contribute to the reduced renal perfusion.
Since the  urinary  concentration of  adenosine  increases  after CM administration,  and 
seems to be related directly to CM osmolality, it is possible that adenosine contributes to the 
haemodynamic renal biphasic response and therefore to the pathogenesis of CIN (18).
Adenosine passes freely through membranes and induces vasoconstriction via links to 
A1  receptors,  and  vasodilatation  via  links  to  A2 receptors.  This  observation  seems  to  be 
confirmed by the tubuloglomerular feedback mechanism that  is  activated by an increase in 
diuresis and natriuresis, secondary to the administration of compounds with high osmolality or 
tonicity, or both. Due to these compounds, the vasoconstriction of glomerular afferent arterioles 
causes an increase in intrarenal vascular resistance followed by a reduction in GFR
It has been suggested that the development of contrast induced nephropathy is affected 
by changes in renal hemodynamics because of the effects of the contrast medium on the action 
of  many  substances,  including  increased activity  of  renal  vasoconstrictors  (vasopressin, 
angiotensin II,  dopamine-1,  endothelin  and  adenosine)  and  decreased  activity of  renal 
vasodilators (nitric oxide and prostaglandins)(19).
The renal vasoconstriction induced by adenosine is accentuated during sodium depletion 
and is reduced during volume expansion. The interaction between adenosine and endothelins as 
mediators of  renal  haemodynamics  is  not  yet  well  defined.  It  has  been hypothesized  that 
diuresis and natriuresis induced by endothelins play a role in determining increases in renal 
tissue-related values  of  adenosine.  Experimental  studies  in  diabetic  animals have  shown 
increases in adenosine-induced renal vasoconstriction; therefore, the higher incidence of CIN in 
diabetics has been attributed to the presumed hypersensitivity of renal vessels to adenosine (21).
Endothelial dysfunction
Active  mediators  such  as  nitric  oxide and prostaglandins  play  an  active  role  in  the 
regulation of renal perfusion. The intrarenal production of these vasodilators is responsible for 
the maintenance of perfusion and oxygen supply in the medulla; therefore, reductions in the 
availability of these mediators can promote nephropathy. It has been suggested that a number 
of factors are implicated in this decrease in nitric oxide concentration during CIN, although the 
role of CM hyperosmolality or of cellular necrosis subsequent to the administration of CM is 
still  doubtful. According to  some recent studies,  CM could induce a depletion  of cofactors 
involved in nitric oxide synthesis, such as tetrahydrobiopterin, or modify substrates, such as L-
arginine(22), or interfere with its synthesis through the nuclear factor κB (NFκB), which inhibits 
mRNA transcription of inducible nitric oxide synthase. Some authors have suggested that that 
role is played by vascular impairment of the endothelium, attributable to metabolic conditions 
(such as hypercholesterolaemia), which subsequently promotes acute renal impairment due to a 
decrease in nitric oxide after CM administration (23).
Experimental studies conducted in animals showed that prostaglandins (PG) also have a 
renal vasodilator effect. PGE1 and PGE2 are able to inhibit endothelin transcription implicated 
in  vasoconstrictive mechanisms;  PGE1 in  particular  seems  to  have  a  direct  cytoprotective 
effect(24).
It  is  highly  probable  that  the  endogenous  vasoactive  system of  endothelins  can 
contribute to CM-induced ischaemic renal damage. In numerous animal and human models, the 
administration of  CM in  large  volumes  has  been  followed  by  increased  plasma and  urine 
endothelin levels, especially in the presence of diabetes mellitus and chronic renal failure.
The  peptidic  isoforms  of  the  endothelin  family—such  as ET1,  ET2  and  ET3—are 
synthesized by a conversion enzyme starting from a common precursor. ET1 is produced in the 
kidney by endothelial  cells,  glomerular  mesangial  cells  and  by  the epithelium of  the  renal 
tubules. There are two different endothelin receptor subtypes: ETA, which is located on vascular 
smooth muscle cells and mediates vasoconstriction; and ETB, which is located on endothelial 
cells and mediates vasodilatation through activating release of nitric oxide and prostacyclin. 
According to  recent  observations,  both  receptors  may  be  involved  in  increasing vascular 
resistance(25),  while the relative contribution of each receptor  to  the  vasoactive  effect  could 
depend upon the specific vascular bed. Endothelins can promote natriuresis and diuresis by 
reducing the reabsorption of sodium in the proximal tubule.
Experiments on CIN in animals showed that endothelin receptor antagonists preserve 
haematic flow and reduce renal vasoconstriction due to the administration of CM. Since this 
also occurs in the presence of a concomitant inhibition of PG-mediated vasodilatation, it seems 
likely  to  support  the  role  played  by  the  endothelin system  in  CM-induced  renal 
vasoconstriction. However, recent studies in patients with impaired baseline renal function have 
failed to demonstrate that endothelin receptor antagonists prevent CIN(26).
Vasoactive mediators
Studies by Arakawa K et al (30) in  anaesthetized dogs without sodium restriction showed 
that  pre-treatment with calcium channel blockers widens the initial phase of vasodilatation that 
follows  the  administration  of  CM  and  cancels  the  following vasoconstriction  phase,  thus 
preventing a reduction in renal flow and GFR. It is therefore likely that the calcium intracellular 
compartment is involved in the renal vasoconstriction that follows infusion of CM.
The calcium ion has a very important role in both tubuloglomerular feedback and the 
myogenic response of the afferent arteriole. The increase in intracellular calcium provokes a 
vasoconstrictive response in intrarenal circulation, and measures to reduce the entry of calcium 
ions into the animal's cells prevent the reduction in RBF and GFR secondary to vasoconstrictor 
stimuli.
A  few  studies  on  the  action  of  angiotensin  II,  also  involved in  tubuloglomerular 
feedback, have been done on sodium-depleted dogs, in which this depletion accentuates both 
the magnitude and duration of the vasoconstrictive phase of the renal blood flow response to 
injection  of  CM,  and the  blockade  of  the  intrarenal renin–angiotensin  system shortens  the 
duration  of  this response(30).  Animal  models  of  acute  renal  failure  have  been induced  by 
administration of a CM bolus, following activation of the renin–angiotensin system by sodium 
restriction and  PG  synthesis  inhibition  with  indomethacin  (31).  Activation of  the  renin–
angiotensin system could cause vasoconstriction of the efferent glomerular arteriole while at the 
same time increasing the  ex novo synthesis of vasodilator prostaglandins resulting in almost 
stable or slightly increased intrarenal resistance. The CM inhibition of PG synthesis negates the 
vasodilator response that in turn increases renal resistance, and reduces kidney perfusion and 
the GFR. 
Blood volume expansion and osmotic load following CM injection provoke a release of 
atrial  natriuretic  peptide  (ANP)  and  antidiuretic hormone  (ADH),  respectively,  with  a 
counteraction  that  provokes direct  renal  effects  in  vivo.  While  vasoconstriction  induced by 
ADH  can  increase  CM-induced  ischaemia,  the  vasodilatory  effects of  ANP  may  play  a 
protective role. It has been observed that the altered plasma concentrations of these mediators 
following CM injection are modest and transient; therefore, it does not seem probable that they 
are the determining cause in the pathogenesis of renal impairment(32). ANP increases hydrostatic 
pressure and GFR, with dilatation of the afferent arteriole and vasoconstriction of the efferent 
arteriole. This peptide blocks tubular sodium reabsorption, induces redistribution of the renal 
medullar  flow, hinders  endothelin-induced  vasoconstriction  and  offers  resistance to 
tubuloglomerular feedback. It  has been observed that this mediator is capable of preventing 
renal  ischaemia  and  nephrotoxicity in  rats  and  dogs  after  CM  injection  (33).  However,  the 
increased serum concentration of atrial natriuretic peptide does not reach values high enough to 
prevent vasoconstriction of the afferent arteriole (34).
Haemorheological factors
Experimental studies performed on rats who have undergone CM administration have 
shown decreases in capillary blood flow in the renal papilla, reductions in erythrocyte velocity 
and O2 tension  and  increases  in  erythrocyte  aggregation.  The  hypertonic  effect  of  high 
osmolality  CM  reduces  the volume  and  deformability  of  the  erythrocyte  membrane, 
contributing to an increase in haematic viscosity and to the worsening of selective medullar 
hypoperfusion:  in  fact,  the  plasma  hyperviscosity can  alter  RBF  particularly  in  the  inner 
medulla, where the haemoconcentration is usually increased. Therefore, most authors agree that 
the peculiar viscosity of some CM can play a role in the pathogenesis of CIN, at least in animal 
studies (35).
Free radicals and reperfusion damage    
Tsao PS et al  (36) showed in animal studies that reactive O2 species, such as hydrogen 
peroxide, hydroxyl radicals, hypochlorous acid and superoxide anion, play a role in CIN, and 
that  endothelial dysfunction  is  partly  due  to  oxygen  free-radical  generation during  post-
ischaemic reperfusion. During the pathogenesis of CM-induced renal damage an association 
has been observed between endothelial dysfunction and post-ischaemic syndrome. Alterations 
in vasoconstriction and perfusion in the external medulla seem to be partially dependent on the 
production of free radicals and a subsequent decrease in or deactivation of nitric oxide, or both. 
Free  oxygen radicals,  particularly the  superoxide  anion,  react  with  nitric  oxide  to  produce 
peroxynitrite, an oxidative and very reactive nitrosative species capable of further reducing the 
bioavailability  of  nitric  oxide,  thereby increasing  tissue  damage.  This  reactive  species  also 
exerts its oxidative and nitrosative effects on the sulf hydrylic groups and aromatic rings of 
proteins,  cellular  membrane  lipids  and nucleic  acids,  and  can  contribute  to  the  acute 
vasoconstrictive effects of CM as well: this occurs through the nitrosation of tyrosine residues 
of enzymes, such as prostacycline synthase and nitric oxide synthase, which are involved in the 
synthesis of medulla vasodilators. The latter may play a critical role in vascular tone control in 
the external medulla, where CM ischaemic damage seems to prevail. In fact, CM administration 
in  humans  is  followed  by  increased production  of  3-nitrotyrosine,  a  stable  marker  of 
peroxynitrite generation  (37).   Patients  with chronic renal  failure,  diabetes mellitus and heart 
failure show alterations in nitric oxide activity, a fact that may explain the greater susceptibility 
of these patients to develop CM-induced nephrototoxicity. 
The  connection  between  vasoactive  mediators  and  free  radicals is  indirectly 
demonstrated by the ability of adenosine to induce the production of O2-reactive species during 
its metabolization to xanthine and hypoxanthine. Methylxanthines,  such as theophylline and 
aminophylline, could behave both as adenosine antagonist and scavengers of hydroxyl groups 
and inhibitors  of  superoxide release.  In  clinical  practice,  premedication with methylxantine 
before CM administration has not produced satisfying results. 
Despite the many animal models of CIN that provide evidence for the involvement of 
free radicals, there is only indirect evidence of free radical involvement in humans. In patients 
with  moderate  renal  failure,  the  administration  of  N-acetylcysteine, an  antioxidant  and 
scavenger of oxygen free radicals, might reduce the incidence of CIN, even if this finding has 
not been uniformly demonstrated by currently available trials (38,39).
Tubular toxicity and immunological mechanisms
In an experimental study conducted on mice, Zager RA et al (40) made the hypothesis that 
direct  tubular  toxicity  may  result from  alterations  in  the  integrity  of  the  plasma  and 
mitochondrial membranes.
Contact of the CM with tubular cells seems to cause a rapid loss of cellular proteins in 
the suspension medium, including the loss of cell  membrane proteins,  such as the sodium–
potassium ATPase pump and caveolin, as well as mitochondrial proteins, such as cytochrome 
C.
The hypothesis that tubular toxicity is associated with CM hyperosmolality seems to be 
supported by the potential of other hyperosmolal substances, such as mannitol and hypertonic 
saline  solution, to  induce analogous morphological  and enzymatic  alterations. Moreover,  in 
dogs some CM reduce paraaminohippurate secretion by 30–40% - a fact that is not evident with 
noniodinated  hypertonic solutions.
Intratubular precipitation of the Bence Jones protein was one of the first hypotheses to 
explain  CIN  associated  with  concomitant multiple  myeloma.  This  theory  has  never  been 
confirmed.  It  has  been  confirmed  that  in  vitro  CM  administration  precipitates the  Tamm 
Horsfall protein, which is the major physiological constituent of the urinary casts.
RISK FACTORS
Risk factors for contrast-medium nephropathy are related to patient characteristics and to 
the contrast medium used.
Patient related factors
The most important patient-specific risk factors are pre-existing renal insufficiency and 
diabetes (5) especially in combination (4).  A history of congestive heart failure is an independent 
risk factor for contrast-medium nephropathy and contributes an even greater risk in patients 
with diabetes or renal disease  (5,  42),   probably because of the effect of low cardiac output on 
renal blood flow. Other  predictors  of  contrast-medium nephropathy include the presence of 
hypertension,  increased  age  (20),  acute myocardial  infarction  within  24  hours  before 
administration of  the  contrast  agent  (5),  hemodynamic  instability  and  use  of  an intra-aortic 
balloon pump during percutaneous coronary intervention (12 , 43). Certain medications, including 
angiotensin- converting-enzyme (ACE) inhibitors  (44) and NSAIDs, have been implicated by 
their effects on regional renal hemodynamics. However, data are sparse and conflicting, some 
evidence  suggests  that  inhibition  of  angiotensin II  may prevent  CIN  (45,  46) but,  in  general, 
support their role in the risk of CIN(47,48). 
Other factors
Risk factors not related to the patient include the type and amount of contrast medium 
administered. The use of hypo-osmolar or iso-osmolar contrast media has been found to be 
beneficial in reducing the incidence of contrast-medium nephropathy among high-risk patients 
but not among patients without risk factors (14, 49). 
The volume of contrast medium administered correlates with the risk of nephropathy (4, 5, 
50).  In  a  series  of  consecutive  patients undergoing  coronary  angiography,  each  100  mL of 
contrast medium administered was associated with a significant increase of 12% in the risk of 
nephropathy.  (5) Adjustment of the volume to the patient's body weight and serum creatinine 
level has been found to minimize the risk (51). 
Similarly, it has been shown that exceeding a patient-specific maximum volume of contrast 
medium  (recommended to  be  5  mL  X[body  weight  (kilograms)/serum  creatinine  level 
(micromoles per litre) ÷ 88.4]) is associated with a 12-fold increase in risk of hemodialysis(50). 
In several large studies, the benefit of nonionic contrast media was limited to patients 
with pre-existing renal dysfunction (52,53,55),  whereas a third study showed no benefit of nonionic 
over ionic contrast agents in patients either with or without pre-existing renal dysfunction (54). A 
recent trial by Aspelin P et al that included diabetic patients with preexisting renal disease 
undergoing  coronary  and  aortic  angiography  supports  the  fact  that  the  lowest-osmolality 
agents, ie, iso-osmolar agents (290 μOsm/kg), provide the best protection from CIN (14).
Risk stratification
Mehran.R and colleagues developed a simple scoring method that integrates 8 baseline 
clinical  variables  to  assess  the  risk of  contrast-medium  nephropathy  after  percutaneous 
coronary  intervention  (12).  Each risk factor  found to  be  statistically  significant  was  given a 
weighted integer and the sum of the integers was considered the total risk for that patient. 
Hypotension  during  the  procedure,  use  of  IABP  during  or  immediately  after  the 
procedure and presence of congestive heart failure was assigned a score of 5 each. 
Age more than 75 years was assigned a score of 4, anaemia and diabetes were assigned a 
score of 3 each, volume of contrast medium used was assigned a score of 1 per 100ml used, 
serum creatinine of >1.5mg/dl was assigned a score of 4 or if e-GFR was calculated by Levey 
modified MDRD formula (105) a score of 2 was assigned for a e-GFR of 40-60, 4 for 20-40 and 6 
for <20 ml/min/1.73m2. 
They found that contrast induced nephropathy was strongly associated with an increased 
risk score: the incidence was 7.5% among patients with a low score and 57.3% among those 
with a high risk score. 
CLINICAL PRESENTATION OF CIN
CIN can occur following any radiographic procedure where intravenous or intraarterial 
contrast agents are used. Acute renal failure caused by contrast medium is usually non-oliguric 
and reversible. The serum creatinine value increases by 48-72 hours following administration 
of contrast medium, peaks by 3-5 days (0.5-3.0mg/dl) and returns to baseline by 7-10 days. 
CIN may also present as  a  more severe acute renal  failure,  particularly  in high risk 
patients. In such situations, oliguria may develop within 24hrs of contrast administration and 
serum creatinine  may  rapidly  increase  sometimes  exceeding  5mg/dl  necessitating  dialysis. 
Most studies though indicate that incidence of CIN requiring dialysis is very low (<1%) but 
with a slightly higher mortality in this group.
It  is  also  important  to  note  that  patients  with  atherosclerotic  disease  undergoing 
angiographic  studies  are  also  at  a  risk  of  developing  acute  renal  failure  secondary  to 
atheroembolic disease. In contrast to CIN, renal failure due to atheroembolic disease has a 
delayed onset (7 days to several weeks), and is associated with a brief period of eosinophilia, 
hypocomplementemia and other evidence of embolic phenomena.
PARAMETERS TO MONITOR RENAL FUNCTION AFTER CONTRAST MEDIUM 
ADMINISTRATION
Serum creatinine 
Serum creatinine is an insensitive measurement in patients with normal kidneys as more 
than 50% reduction in GFR may occur before any rise is observed. However it can be used as 
an accurate test in patients with renal impairment to assess any further deterioration in renal 
function after administration of contrast medium (106). 
Creatinine clearance 
Creatinine clearance is often used as a measurement of GFR. However creatinine is not 
a perfect marker for GFR as it is both filtered by the glomerulus and secreted by the tubules. 
However this measurement remains the most acceptable method for assessing renal function in 
clinical practice(80) 
GFR is calculated by a formula by Cockroft and Gault(94) using serum creatinine, body 
weight and age. 
CrCl = [(140 - age) x IBW] / (Scr x 72)      (x 0.85 for females)
Measurement of urinary enzymes 
Urinary excretion of proximal tubular brush border enzymes (alanine aminopeptidase  α-
glutamyl transferase  and alkaline phosphatase), lysosomal enzymes (β-glucuronidase, N-acetyl 
β-D-glucosaminidase) and cytosol enzymes (lactate dehydrogenase, leucine aminopeptidase, β-
glucosidase) are often raised following administration of contrast medium. 
Enzymuria peaks during the first 6 hours following contrast medium administration and 
recovers ain 24-48 hours. It represents the Normal response of the kidneys to contrast medium 
exposure and is of little importance in the assessment of CIN.
PREVENTION
Modification of risk factors
In order to minimize the risk of CIN, when possible the administration of contrast media 
should be delayed in patients with circulatory collapse or congestive heart failure until their 
hemodynamic  status  is  corrected.  Administration should  be  delayed  for  24  hours  after 
myocardial infarction. Repeated exposure should be delayed for 48 hours in patients without 
risk factors for contrast-medium nephropathy, and for 72 hours in those with diabetes mellitus 
or  pre-existing  renal dysfunction.  NSAIDs,  diuretics  (when  feasible) and  possibly  ACE 
inhibitors should be discontinued 1–2 days before administration of contrast media.(56) Most 
importantly, the smallest possible amount of nonionic, hypo-osmolar or iso-osmolar contrast 
medium should be used in patients with risk factors.
THERAPEUTIC APPROACHES TO PREVENTION OF CIN 
Saline hydration and forced diuresis:
A standardized saline hydration protocol has been proven effective in reducing the risk 
of contrast induced nephropathy and has been recommended for use routinely (7, 57, 58, 59 ). In a 
study of the effectiveness of saline, mannitol and furosemide in preventing contrast-medium 
nephropathy after cardiac angiography in patients with renal  insufficiency, the incidence of 
nephropathy  was significantly lower among patients  who received saline  alone (11%) than 
among those who received saline plus mannitol (28%) or saline plus furosemide (40%). It was 
also considerably lower than the incidence reported among patients with similar pre-existing 
renal diseases who did not receive hydration in a standardized fashion (4,61)  These results were 
confirmed  by  the  Prevention  of  Radiocontrast Induced  Nephropathy  Clinical  Evaluation 
(PRINCE) Study  (57), which found no benefit to forced diuresis with intravenous crystalloid, 
furosemide, mannitol or low-dose dopamine therapy over hydration alone in patients exposed to 
contrast media who were at risk for nephropathy.
In a recent prospective randomized studies by Merten GJ et al hydration with sodium 
bicarbonate was found to be significantly more effective than hydration with sodium chloride in 
preventing contrast-medium  nephropathy  (incidence  of  nephropathy  1.7%  v. 13.6% 
respectively)  (60).  However, further studies are required to clarify the role of hydration with 
sodium bicarbonate in preventing such nephropathy.
VASODILATORS
1. Fenoldopam 
Fenoldopam mesylate is a selective dopamine-1 receptor agonist that produces systemic, 
peripheral  and  renal  arterial vasodilatation.  The  drug  exhibits  many  desirable  renal  effects 
including decreases in renal vascular resistance and increases in renal blood flow, glomerular 
filtration rate, and sodium and water excretion (62). The benefit of fenoldopam for the prevention 
of contrast-medium nephropathy has been demonstrated in a dog model and in nonrandomized 
clinical studies (62,63). In a small double-blind, randomized controlled pilot trial, fenoldopam plus 
normal saline was found to attenuate reductions in renal blood flow induced by contrast media; 
it was also associated with a lower incidence of contrast-medium nephropathy than was normal 
saline alone, although the difference between the 2 groups was not significant (65). In 2 recent 
large studies comparing fenoldopam with N-acetylcysteine, treatment with fenoldopam either 
had  a  similar,  nonsignificant effect  as  that  of  N-acetylcysteine(66) or  was  inferior  to  it  (67). 
Therefore, the routine use of fenoldopam cannot be recommended at the present time.
2. Low dose dopamine 
Low-dose dopamine has been used to maintain renal perfusion and function in patients 
with renal insufficiency who have circulatory or hemodynamic instability. However, studies 
evaluating low-dose dopamine (2–5 µg/kg per minute) for the prevention of contrast-medium 
nephropathy have shown conflicting results  (68,69,70).   These different results may be related to 
the simultaneous activation of the dopamine receptor type 2 (DA2), which, in contrast to the 
DA1 receptor, reduces renal blood flow and the glomerular filtration rate.
3. Adenosine antagonists
Contrast media stimulate the intrarenal secretion of adenosine, which binds to the renal 
adenosine  receptor and  acts  as  a  potent  vasoconstrictor,  reducing  renal  blood  flow and 
increasing  the  generation  of  oxygen  free  radicals  as  it is  metabolized  to  xanthine  and 
hypoxanthine. Studies evaluating the adenosine antagonists (aminophylline and theophylline) 
have shown inconsistent results  (70,71,72,73),  and therefore the use of   these antagonists are not 
routinely recommended for the prevention of contrast-medium nephropathy.  
4. Other vasodilator therapies
The calcium-channel antagonists verapamil and diltiazem have been found to attenuate 
the renal vasoconstrictor response after exposure to radiocontrast media  (74).  However, when 
the  efficacy of  the  dihydropyridine  calcium-channel  blockers  felodipine, nitrendipine  and 
nifedipine was evaluated, results were inconsistent (75,76).
Endothelin-1,  a  potent  endogenous  vasoconstrictor,  is  thought to  play  a  role  in  the 
development of contrast-medium nephropathy. However, the use of a mixed endothelin A and 
B antagonist (SB 290670) was associated with a significantly higher incidence of nephropathy 
than was placebo (77).  Prostaglandin E1 (PGE1) has vasodilatory effects that may be beneficial in 
preventing contrast-medium nephropathy. In one study, 130 patients were randomly assigned to 
receive either placebo or 1 of 3 doses of PGE1. All of the patients received 2 L of fluid before 
and after the contrast procedure. The increase in serum creatinine level was smaller in all of the 
3 PGE1 groups than in the placebo group, but the difference was significant only in the medium-
dose PGE1 group (20 ng/kg per minute) (78).
Antioxidants
N-acetylcysteine 
N-Acetylcysteine  is  an  acetylated  amino  acid  (L-cysteine)  with  reactive  sulfhydryl 
groups that confer antioxidant properties. N-acetylcysteine reduces renal damage by scavenging 
oxygen free radicals, generated as a result of toxic damage to renal tubules (8).  In a randomized 
placebo-controlled clinical  trial,  N-acetylcysteine  significantly  reduced urinary levels  of  15-
isoprostane F2t, a specific marker of oxidative stress (79).  N-acetylcysteine may also have direct 
vasodilating effects on the kidneys through an increase in the biologic effects of nitric oxide, 
which is a potent and stable vasodilator contributing to improved renal hemodynamics (79).
In  a  study  comparing  oral  administration of  N-acetylcysteine  plus  standard  saline 
hydration with hydration alone in patients with chronic renal insufficiency undergoing coronary 
angiography with intravenous administration of 75 mL of a nonionic, hypo-osmolar contrast 
agent(8),  the  incidence of  contrast-medium  nephropathy  was  significantly  lower  in  the N-
acetylcysteine group than in the control group. 
Subsequent trials of N-acetylcysteine in patients with chronic renal insufficiency have 
provided conflicting results(9,66 ,81,82).  A meta-analysis of the first 7 reported trials showed that, 
compared  with  peri-procedural  hydration  alone, administration  of  N-acetylcysteine  plus 
hydration  reduced  the risk  of  contrast-medium  nephropathy  by  56%  among  patients  with 
chronic renal insufficiency (83).
A meta-analysis by Goldenberg I et al in 2004 showed an overall benefit of the drug,  but 
only in patients with more severe renal dysfunction (serum creatinine level > 221 µmol/L) or 
when a nonstandard or incomplete hydration protocol was used (84).
Given the  mixed results  of  N-acetylcysteine  studies  and the lack  of  evidence-based 
consensus, only a general recommendation for the use of the drug is made at this time by most 
authors. It may be used to prevent contrast-medium nephropathy in high-risk patients and as an 
abbreviated oral or intravenous regimen in patients requiring emergency diagnostic procedures 
using contrast  media.  An oral  dose  of  600 mg twice  daily  the  day  before  and the  day  of 
procedure is the most commonly used regimen. IV doses of 150 mg/kg over half an hour before 
the procedure or 50 mg/kg administered over 4 hr have more recently been gaining popularity 
for use in critically ill patients or in those who are unable to take NAC orally (85).
Ascorbic acid
A recent randomized trial showed that the use of ascorbic acid was associated with a 
significant reduction of 62% in the rate of contrast-medium nephropathy among patients with 
renal insufficiency undergoing coronary angiography with or without intervention (86).  Further 
prospective studies are needed to validate these preliminary results.
Haemofiltration and Haemodialysis
In a study by Vogt B et al, hemodialysis immediately after exposure to contrast media 
has not been shown to be effective in preventiing nephropathy in patients with pre-existing 
renal  insufficiency,  and  it  may  even increase  the  risk  of  nephropathy  (87).  Marenzi  et  al 
published a paper in 2003 studying the use of hemofiltration as a  prophylactic  measure to 
prevent CIN (88). In a higher-risk patient population (mean serum creatinine level 265 µmol/L), 
hemofiltration seems to have a protective effect, including significant reduction in in-hospital 
and 1-year mortality compared with routine hydration. However, the expense and complexity 
of  hemodialysis  may  prevent its  general  application  in  procedures  that  require  the  use  of 
contrast media.
METHODS AND MATERIALS
STUDY POPULATION
All patients included in the study were patients who underwent cardiac catheterization 
studies  during  the  period  from  Jan  2005-  July  2006  in  the  Department  of  Cardiology, 
Government  General  Hospital.  All  procedures  were  elective,  no  emergency  procedure  was 
included in the study, thereby ruling out patients with MI within the previous 72 hours from the 
study. None of the patients included in the study had any prior angiographic study within the 
previous week. Hydration status was assessed clinically. No specific hydration protocol was 
followed in the patients.
STUDY DESIGN
Contrast induced nephropathy was defined as an increase in post-procedural creatinine 
by more than 25% from the  baseline.  All  patients  who had an increase  in post-procedural 
creatinine  by  more  than  25%  over  baseline  were  diagnosed  to  have  Contrast  Induced 
Nephropathy. Serum creatinine was estimated by ERBA XL 300 automated analyzer using 
Alkaline  picrate  method  in  our  Biochemistry  department.  Serum  creatinine  values  were 
followed up in the patients before coronary angiogram was performed and at 24 and 48 hours 
after  the  procedure,  and  peak  serum  creatinine  levels  were  considered  for  calculation  of 
increase from baseline. 
Patients were identified as hypertensives if already diagnosed and on treatment or newly 
detected with a Blood pressure of 140/90 or more as defined by JNC 7 (89).                
Patients with Diabetes mellitus were defined as known diabetics on treatment or patients 
with a random blood sugar value of >200mg/dl as defined by ADA guidelines  (92,  93). Blood 
glucose  level  was  measured  using  Glucose  oxidase  and  Pyruvate  oxidase  methods  by  the 
automated analyzer.
"Anemia" was defined using World Health Organization criteria: baseline hematocrit 
value <39% for men and <36% for women(90).   
Serum  cholesterol  was  measured  using  enzymatic  method,  serum triglyceride  using 
enzymatic  colorimetric  method  and  serum HDL-C using  Polyethylene  Glycol-CHOD-PAP 
method by the automated analyzer. Dyslipidemia was defined by ATP3 guidelines (91)  as Total 
cholesterol > 200mg/dl, LDL-C >130mg/dl, HDL-C < 40 in men and <50 in women, TGL > 
150mg/dl.  Lipoprotein anaysis was performed on serum obtained after a 12 hour fast. Total 
cholesterol, HDL-C and TGL were measured and LDL-C was calculated using the Friedwald’s 
formula 
LDL-C = Total cholesterol - HDL-C – (TGL/5)
Height and weight of  all  patients  was documented and Body Mass Index calculated 
using the formula  
BMI = (weight in kg)/ (Height in metres2)
Urine  output  of  the  patient  was  monitored.  Urine  albumin,  echocardiogram  for 
quantification of Left Ventricular function and renal angiogram was also performed to rule out 
possibility of renal artery stenosis.  All patients were screened with a urine examination for 
albuminuria and an ultrasound of the abdomen to rule out underlying primary renal disease. 
None of the patients included in the study had underlying renal disease.
The contrast media used were ionic monomer Diatrizoate (high osmolar) and non-ionic 
monomer Iohexol (Low osmolar). Use of high or low osmolar contrast medium was subject to 
availability and presence of Left Ventricular dysfunction or renal failure in view of the high 
cost of low-osmolar contrast medium.
All patients were observed for development of hypotension, anaphylactoid reactions to 
contrast  medium,  or  any  other  procedural  complication  during  and  immediately  after  the 
angiogram. None of the patients in the study developed any significant hypotension during the 
procedure requiring inotropic support  and no patient  developed any serious  reaction to  the 
contrast medium. 
No  specific  prophylactic  measure  was  used  towards  prevention  of  contrast  induced 
nephropathy. 
STATISTICAL  ANALYSIS
Statistical  analysis  was carried out for 122 subjects  after  categorizing each variable. 
Baseline data were collected from all patients. Age, sex, presence of hypertension, diabetes, 
BMI, serum creatinine, creatinine clearance, type and amount of contrast medium, number of 
coronary vessels diseased, presence of dyslipidemia and  left ventricular ejection fraction were 
analyzed with respect to development of CIN. 
Results are presented as mean ± SD or a percentage of the total. The significance of 
difference in means between two groups was calculated by means of Student’s t test and the 
significance of difference in proportions were compared with Pearson’s χ2 (chi-square) test. 
Statistical significance was taken to be significant at 1% level  when P value was  < 0.001, 
significant at 5% level when P value was between 0.011 to 0.05, and not significant at 5% level 
when P value was >0.05.
Logistic regression was used to identify correlates of CIN. Models were developed with 
stepwise techniques and by consideration of variables that were clinically relevant. Variables 
included  are  baseline  creatinine  value,  type  of  contrast  used,  amount  of  contrast  used, 
hypertension, baseline creatinine clearance and number of diseased coronary vessels. Statistical 
analysis was carried out using standard formulae SPSS (Statistical package for Social Sciences) 
for Windows Dos.
OBSERVATIONS
BASELINE CHARACTERISTICS OF STUDY POPULATION
n = 122
Frequency Percentage
Sex Male 104 85%
Female 18 15%
Age Group < 50 47 39%
51-60 53 43%
> 60 22 18%
Hypertension 56 46%
Diabetes 41 34%
BMI < 25 87 71%
> 25 35 29%
Out of the total population studied, females were fewer in number forming only 15%. 
Patients aged >60 years formed 18% of the study population. Patients with risk factors like 
hypertension and diabetes mellitus formed 46% and 34% of the study population respectively.
AGE GROUPS
Variable
CIN No CIN
n % n %
p
Age
<50 6 12.8% 41 87.2%
51-60 4 7.5% 49 92.5%
>60 8 36.4% 14 63.6%
0.005**
Among patients aged >60 years the incidence of CIN was 36.4% which was found to be 
statistically significant with a p- value of 0.005.
SEX
Variable
CIN No CIN
n % n %
p
Sex
M 15 14.4% 89 85.6%
F 3 16.7% 15 83.3%
0.800
The incidence of CIN among females was marginally more than that among males, but 
this was found to be statistically not significant.
HYPERTENSION
Variable
CIN No CIN
n % n % p
HT 11 19.6% 45 80.4% 0.160
The  incidence  of  CIN in  hypertensives  was  19.6% which  was  also  statistically  not 
significant.
DIABETES MELLITUS
Variable
CIN No CIN
n % n % p
DM 9 22.0% 32 78.0% 0.110
22% among the diabetics developed CIN which was not statistically significant with a p-
value of > 0.05
BODY MASS INDEX
Variable
CIN No CIN
n % n %
p
BMI
< 25 13 14.9% 74 85.1%
> 25 5 14.3% 30 85.7%
0.930
Patients were grouped based on BMI of  >25 (overweight).  There was no significant 
difference in the incidence of CIN between the two groups.
                                        BASELINE SERUM CREATININE
Variable
CIN No CIN
n % n %
p
Creatinine
< 1.5mg/dl 15 13.2% 99 86.8%
> 1.5mg/dl 3 37.5% 5 62.5%
0.003**
A baseline pre-procedure serum creatinine of >1.5 mg/dl was found to be a statistically 
significant risk factor with an incidence of CIN of 37.5% and a p-value of 0.003 
LEFT VENTRICULAR EJECTION FRACTION
Variable
CIN No CIN
n % n % p
LVEF
< 40% 5 38.5% 8 61.5%
> 40% 13 11.9% 96 88.1%
0.011*
A decreased Left ventricular ejection fraction of <40 % was found to be significant at 
5% level with an incidence of CIN of 38.5% and a p-value of 0.011
DYSLIPIDEMIA
Variable
CIN No CIN
n % n % p
Dyslipidemia 5 27.8% 13 72.2% 0.091
The incidence of CIN in patients with an abnormal lipid profile was 27.8% which was 
not statistically significant.
TYPE OF CONTRAST MEDIUM USED
Variable
CIN No CIN
n % n %
p
Contrast
HOCM 16 15.4% 88 84.6%
LOCM 2 11.1% 16 88.9%
0.640
The incidence of CIN in patients with use of HOCM was higher at 15.4% compared to 
11.1% with LOCM, though statistically not significant.
NUMBER OF CORONARY VESSELS DISEASED:
Variable
CIN No CIN
n % n %
p
Cor. Vessels
< 1 2 7.1% 26 92.9%
> 1 16 17.0% 78 83.0%
0.196
Multivessel  disease  increased  the  incidence  of  CIN  compared  to  normal  coronary 
vasculature by angiogram or single vessel disease. P-value was 0.196 making it statistically not 
significant.
Student’s t test was performed for the difference between two means for the following 
variables:
CIN No CIN
Mean +SD Mean +SD
p
Sugar 104.22 28.13 95.05 23.12 0.135
Urea 25.67 6.1 24.28 4.86 0.284
Creatinine 1.18 0.29 0.97 0.22 < 0.001**
Cr Clearance 67.89 24.75 83.23 17.04 0.001**
Hb 11.57 0.85 11.54 1.09 0.923
PCV 34.22 3.1 34.05 3.48 0.842
ESR 13.67 5.75 16.24 7.24 0.156
LVEF 51.83 14.04 55.53 11.2 0.216
Amount  of 
Contrast      82.22 13.09 55.19 13.44 < 0.001**
* indicates statistical significance at 5% level 
** indicates statistical significance at 1% level
The average values of baseline parameters including blood sugar, urea, serum creatinine 
were higher among the patients who developed CIN than among those who did not.  The LVEF 
and creatinine clearance at baseline were noted to be less among patients with CIN than those 
without.  The  average  amount  of  contrast  used in  patients  who developed CIN was  82  ml 
compared to an average of 55 ml in those who did not develop CIN. Among these variables 
studied, baseline serum creatinine, creatinine clearance and amount of contrast used were found 
to be statistically significant risk factors.
Logistic  regression was performed by entering the following variables for predicting 
CIN. The variables were, serum creatinine, creatinine clearance, type of contrast used, amount 
of contrast used, presence or absence of hypertension and presence or absence of multivessel 
disease. The development of CIN could be predicted to an overall accuracy of 94% with a 78% 
correct chance of predicting development of CIN with these variables.
All the above mentioned parameters were found to be predictors of CIN by this model.
DISCUSSION
Our study has  attempted to assess the  incidence of  contrast  induced nephropathy  in 
patients undergoing cardiac catheterization studies in our hospital and to identify the major risk 
factors for developing CIN in this population. 
The major findings of this study are that the incidence of contrast nephropathy is as high 
as 14.75% among the population undergoing cardiac catheterization studies at our Institute. 
The rates of contrast induced nephropathy reported in various studies that included patients 
with pre-existing renal dysfunction or diabetes mellitus in whom a standard hydration protocol 
was not administered is between 12% and 26 % (4, 7, 12). No patient in our study developed acute 
renal failure necessitating Haemodialysis. The incidence of ARF requiring haemodialysis has 
been reported in most studies as <1%. 
McCullough PA et al also reported an increase in serum creatinine by 25% in 14.5% of 
patients  who underwent coronary angiography (95 percent confidence interval,  12.9 to 16.1 
percent)  (4). An incidence of 16.5% was reported by Iakovou I et al  (20), who also reported an 
increased incidence of CIN among females. In our study females form only 15% of the study 
population but the incidence of CIN among them was 16.6%, higher than the incidence among 
males (14.4%), comparable with the incidence reported by Iakovou et al though not found to be 
statistically significant. 
Most studies performed internationally have found that the risk of CIN increases with 
increasing age and age >75 years was a significant risk factor for development of CIN. The 
study by Mehran et al in 2004 puts the incidence at as high as 21.8% among those aged >75 
years (12). The cause is probably multifactorial and related to alterations in renal glomerular and 
tubular functions and perhaps to renovascular disease. Our study shows that incidence of CIN 
does increase with increasing age, with the population above 60 years  having an incidence as 
high as 36%. Age has also been found to be a statistically significant factor in development of 
CIN in our study.
That  osmolality  is  an  important  factor  in  contrast-medium–induced nephropathy  is 
supported by several studies. In a prospective, randomized study involving 1196 patients who 
underwent  angiocardiography, Rudnick  et  al  (52) found  no  differences  in  the  incidence  of 
nephropathy (defined as an increase of 0.5 mg per deciliter or more in the serum creatinine 
concentration within 72 hours after the administration of contrast medium) between patients 
receiving  iohexol  (low-osmolar; 780  mOsm per  kilogram of  water)  and  patients  receiving 
diatrizoate (high-osmolar; 1870 mOsm per kilogram of water) among low-risk patients (patients 
without diabetes who had a base-line serum creatinine concentration of less than 1.5 mg per 
deciliter  [133 µmol  per  liter]).  However,  among  patients  without  diabetes whose  serum 
creatinine concentrations were higher than 1.5 mg per deciliter, the incidence of nephropathy 
was reduced from 27.0 to 12.2 percent by the use of iohexol (52) Among patients with diabetes, 
the incidence was reduced from 47.7 to 33.3 percent. Overall, patients receiving high-osmolar 
contrast medium were 3.3 times as likely to have nephropathy induced by contrast medium as 
those  receiving  low-osmolar  contrast  medium  (52).   Barrett  and  Carlisle  performed  a  meta-
analysis to determine the relative nephrotoxicity of contrast mediums using the results of 14 
trials  and concluded that  the use of low-osmolar contrast medium rather than high-osmolar 
contrast medium was beneficial to patients with preexisting renal failure (49). A similar pattern 
was observed by Aspelin et al in a study conducted in 2003(14).  Our study revealed a slightly 
higher incidence of CIN among patients in whom HOCM was used was 15.4% compared to an 
incidence  of  11.1%  among  those  in  whom  LOCM  was  used.  But  the  figures  were  not 
statistically significant. The type of contrast was found to be an predictor of renal function 
deterioration by logistic regression. 
Use of LOCM was restricted to patients in whom there was significant left ventricular 
dysfunction or elevated renal parameters. Its use was mainly limited by cost factors. LOCM 
was used in only 15% of the study population especially those with high risk. 
In  most  studies,  the  volume  of  contrast  medium  administered  during  coronary 
angiography correlates with the risk of CIN (5, 51, 96, 100 ). A study of more than 7000 patients by 
Rihal CS et al showed that each 100 mL of contrast medium administered correlates with a 
hazard ratio for CIN of 1.12 (5). In our study, the average amount of contrast used among those 
patients who developed CIN was more than that used among patients who did not develop CIN 
(82ml vs 55 ml). This was also found to be statistically significant with a p-value of <0.001. 
The amount of contrast used was also found to be an independent predictor of CIN by logistic 
regression. The lesser the amount of contrast used, the lesser the incidence of CIN expected. 
Baseline renal  insufficiency is also an important risk factor for CIN. Several studies 
have shown an increased incidence of CIN among patients with pre-existing renal failure (95, 5). 
Rihal et al in a study observed 22.4% incidence of CIN among patients with baseline serum 
creatinine of between 2-2.9mg/dl, and 30.6% among those with baseline value of >3.0mg/dl(5). 
Murphy  SW et  al  also  noted  that  the  individuals  with  chronic  renal  insufficiency  (Serum 
creatinine >= 2.0mg/dl) were at a greater risk of contrast induced renal injury (16).
In many studies preexisting renal disease has been the greatest independent predictor of 
CIN, and its severity (as measured by serum creatinine concentration) directly correlating with 
the incidence of CIN (5, 13, 20). In a study by Gruberg et al that included 439 patients with serum 
creatinine levels of 1.8 mg/dL or higher before coronary angiography, the incidence of CN was 
37%; 7.1% and 0.9% of the patients underwent short-term and long-term dialysis, respectively 
(98). Similar pattern was also noted in studies conducted by Mehran et al (12), Manske CL et al (96). 
Our  study  also  showed a  similar  pattern,  with  a  baseline  serum creatinine  value  of 
>1.5mg/dl being observed to be a statistically significant risk factor for the development of 
CIN. It was also noted in our study that the baseline creatinine clearance as calculated by the 
Cockroft and Gault formula was lower (67.89 ml/min) in the study population who developed 
CIN compared to those who did not (83.23ml/min). Creatinine clearance was also observed to 
be a  statistically  significant  risk factor  with a  p-value  of  0.001.  It  was  also found to  be a 
significant independent predictor of deterioration of renal function by logistic regression. 
Diabetics were found to have a higher incidence of CIN in our study. Most studies also 
report a similar picture (5, 12). Mehran et al reported an incidence of 19.2% in diabetics (12). CIN 
incidence rates among diabetics have been reported to be between 5%- 30% in various studies 
(42, 97). In our study diabetes was not found to be a statistically significant risk factor though the 
incidence of  CIN was 22% among the  diabetics.  A study by Gruberg L et  al  also reports 
diabetes as not being a statistically significant risk factor in univariate analysis (98).
Hypertension was reported to be an independent predictor of CIN in the study conducted 
by Iakovou I et al (20). The study by Mehran R et al also finds hypertension to be a significant 
predictor of CIN with 15.9% among hypertensives developing CIN (12). The study by Gruberg L 
et al does not find a statistically significant association between hypertension and CIN (98). In 
our  study the  incidence  of  CIN in  hypertensives  was  19.6% but  there  was no  statistically 
significant association between hypertension and CIN. However it was found to be a significant 
risk factor in predicting development of CIN by logistic regression. 
Body Mass Index was not found to be a statistically significant risk factor in our study. 
No study has been done to correlate BMI with CIN. There has been one study by Omer Toprak 
et al published in March 2006 which showed an increased risk of CIN among patients with 
metabolic syndrome. In this group of patients it was reported that impaired fasting glucose, 
high triglyceride levels were independent predictors of risk of CIN (106).
Dyslipidemia in our study defined as per ATP 3 guidelines was found to be statistically 
not significant as a risk factor for CIN. 27.8% of patients with dyslipidemia developed CIN in 
our  study.  Hypercholesterolemia  has  been  shown  to  be  a  significant  risk  factor  for  the 
development of CIN in the study by Mehran R et al with an incidence of CIN being 13.2% (12). 
Hypertriglyceridemia has been shown to be a significant risk factor for CIN in the study by 
Omer Toprak et al (102). There has also been an animal study by Andrade L et al which shows 
that hypercholesterolemia in rats aggravates radio contrast nephropathy (103). 
Multiple coronary vessels being diseased as detected by coronary angiogram was not a 
significant  risk factor  statistically.  Incidence  of  CIN in  patients  with two and three  vessel 
disease was 17 %. However by logistic regression it was an independent predictor of CIN. It 
has also been documented as a significant risk factor for CIN in studies by Mehran R et al (12) 
and Omer Toprak et al (102, 104). 
Studies  have shown that  reduced left  ventricular  ejection fraction (≤49%),  advanced 
congestive  heart  failure  (New York  Heart  Association  class  III  or  IV),  or  any  history  of 
congestive heart failure are independent risk factors for CN and contribute even greater risk in 
patients with diabetes or renal disease (5, 96, 98) A recent study conducted by Marenzi.G et al has 
reported a  Left  ventricular  ejection fraction of  <40% as  being a significant  risk factor  for 
development of CIN following primary angioplasty  (101). The risk associated with congestive 
heart failure is likely due to derangements in renal blood flow due to low cardiac output. The 
risk is probably increased by this population’s use of specific medications such as angiotensin-
converting enzyme (ACE) inhibitors, diuretics, and aspirin(99). Our study showed an incidence 
of CIN to be 38.5% among patients with an LVEF <40%, which was statistically significant at 
5% level with a p-value of 0.011. 
Apart  from  these  factors,  acute  hyperglycemia  defined  as  a  blood  sugar  value  of 
>150mg/dl has been shown to be a significant risk factor in the development of CIN in one 
study by Diane.B.Turcot et al (64). There were only 5 patients in our study with a blood sugar 
value >150 mg/dl, out of which only one developed CIN. This parameter was not assessed due 
to very small numbers. 
This study has shown that risk factors for CIN are an elevated baseline creatinine, a low 
creatinine  clearance,  the  type  and  amount  of  contrast  medium  used,  and  the  presence  of 
multivessel CAD.  Identification of these risk factors before subjecting the patient to angiogram 
gives us an opportunity to use prophylactic measures to prevent CIN and also anticipate CIN in 
high risk patients. 
OUR STUDY HAD SEVERAL LIMITATIONS
Patient’s hydration status was assessed clinically, central venous pressure monitoring 
was not done for patients due to resource constraints. All patients were on overnight starvation 
before the procedure, some were on diuretics for their cardiac condition, and no patient was 
given  intravenous  fluid  infusion.  Dehydration  has  been  consistently  identified  to  be  a 
significant  risk factor  for  CIN in most  studies.  A more careful  assessment  of  hydration is 
required to study statistical significance of dehydration as a risk factor. 
Almost all patients were on ACE inhibitors for their cardiac condition which could be a 
confounding  factor  in  the  study.  Studies  regarding  the  role  of  ACE  inhibitors  have  been 
conflicting. 
There was also no strict protocol with regard to the type of contrast medium used as it 
was dependent essentially on availability due to cost factors. 
CONCLUSION
The conclusions that can be drawn from this study are:
There  is  a  significant  risk  of  contrast  induced  nephropathy  in  patients  undergoing 
cardiac catheterization studies especially among the elderly, and among those with pre-existing 
renal failure. 
* The risk of CIN is also increased by the presence of multivessel coronary disease by 
angiogram and by the presence of left ventricular dysfunction
* There were no patients in this study who developed renal failure needing Haemodialysis. 
* The type of contrast and amount used also determine development of   CIN.
* Risk of CIN can be predicted before the procedure based on risk factors and suitable 
precautions can be taken including use of low or iso-osmolar contrast media, minimizing 
the amount of contrast medium used. 
SUMMARY
Contrast  induced  nephropathy  is  a  significant  problem in  clinical  practice  with  the 
increasing use of contrast media in diagnostic and interventional procedures. In our hospital we 
conducted  a  study  of  the  incidence  of  contrast  -  induced nephropathy  among  the  patients 
undergoing cardiac catheterisation studies, based on the increase in post - procedural serum 
creatinine from the baseline.
It was noted that among the 122 patients followed up in the Department of Cardiology 
18  developed  CIN  (14.75%).  Among  the  patients  who  developed  CIN,  it  was  noted  that 
common risk factors  were  increased Age,  elevated baseline  serum creatinine,  low baseline 
creatinine clearance, and multi-vessel coronary disease. It was also noted that incidence of CIN 
was  higher  among patients  with  hypertension,  diabetes,  poor  LV function,  and among the 
patients  who  underwent  studies  with  high  osmolar  contrast  medium and  in  whom higher 
amounts of contrast medium was used. Identification of these risk factors before subjecting the 
patient to angiogram studies gives us an opportunity to anticipate development of CIN and to 
use prophylactic measures to prevent CIN. 
SCOPE FOR FUTURE STUDIES
This  study  identifies  only  potential  risk  factors  of  Contrast  Induced  Nephropathy. 
Further studies need to be done regarding possibility of preventing CIN, various prophylactic 
measures that might be useful in a Government Hospital setting. This study has not included 
patients undergoing emergency angiographic procedures like PTCA etc. In such conditions the 
risk factors are likely to be more and unique to the situation. A study in such a setting will help 
define the risks better. A long term follow up of patients who develop CIN could be done to 
determine the degree of residual renal damage and possibility of permanent renal dysfunction 
leading  to  Chronic  Kidney  Disease.  A  thorough  study  regarding  the  relationship  between 
atheromatous disease load and CIN can also be done considering the fact that dyslipidemia, 
multivessel CAD have been known to predispose to CIN.
              ABBREVIATIONS AND ACRONYMS
CIN - Contrast Induced Nephropathy
PCI – Percutaneous Intervention
CM – Contrast Medium
HOCM - High Osmolar Contrast Medium
LOCM - Low Osmolar Contrast Medium
RBF - Renal Blood Flow
GFR - Glomerular Filtration Rate
PG - Prostaglandin
ANP - Atrial Natriuretic Peptide
ADH – Anti-diuretic Hormone
ACE – Angiotensin Converting Enzyme
NSAID – Non Steroidal Anti-Inflammatory Drugs
IABP – Intra Aortic Balloon Pump
Sr.Cr. - Serum Creatinine
CrCl – Creatinine Clearance
MDRD – Modification Of Diet in Renal Disease
HDL-C – High Density Lipoprotein
LDL-C – Low Density Lipoprotein
TGL – Triglycerides
BMI – Body Mass Index
HT – Hypertension 
DM – Diabetes Mellitus
LVEF – Left Ventricular Ejection Fraction
Hb – Haemoglobin
PCV – Packed Cell Volume
ESR – Erythrocyte Sedimentation Rate
CAD – Coronary Artery Disease
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PROFORMA
Name
Age
Sex
Occupation
Hospital IP no.
Admitting diagnosis:
Procedure planned: 
Indication for procedure:        
   
Risk factors:
1. Hypertension:
2. Diabetes mellitus:
3. Drug intake(nephrotoxic):
General examination:     
Ht:
Wt:
Hydration status:
Vitals: Pulse:
Blood pressure:
Respiratory rate:
Investigations at admission:
1. Blood sugar:
2. Blood Urea:
3. Sr. Creatinine:
4. Sr. Potassium:
5. Sr. Sodium:
6. Hb: 
7. PCV:                
8. ESR:
9. Urine Albumin:
10. USG abdomen:
11. Echocardiogram:
12. Sr. Lipid profile: 
Procedure done:
Contrast used:
Amount of contrast used:
Osmolality of contrast:
No. of coronary vessels involved:
Renal Artery Stenosis (>50%):    Y/N 
Post-procedure:
 Day 0 24hrs 48/72hrs
Urine output
Sr creatinine
Creatinine clearance *
* as calculated by Cockroft and Gault formula
Peak Sr.creatinine:
% increase from baseline:

